Tofacitinib for the Treatment of Pyoderma Gangrenosum

Kochar, Bharati and Herfarth, Neel and Mamie, Céline and Navarini, Alexander A. and Scharl, Michael and Herfarth, Hans H.. (2019) Tofacitinib for the Treatment of Pyoderma Gangrenosum. Clinical gastroenterology and hepatology, 17 (5). pp. 991-993.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/72191/

Downloads: Statistics Overview


Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.; 1; We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialfächer (Klinik) > Dermatologie USB > Dermatologie (Navarini)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialfächer (Klinik) > Dermatologie USB > Dermatologie (Navarini)
UniBasel Contributors:Navarini, Alexander
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:10 Jul 2020 09:12
Deposited On:10 Jul 2020 09:12

Repository Staff Only: item control page